Portal de Periódicos da CAPES

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

2014; Massachusetts Medical Society; Volume: 371; Issue: 5 Linguagem: Inglês

10.1056/nejmoa1405095

1533-4406

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, Yohann Loriot, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury, Ian D. Davis, Johann S. de Bono, Christopher P. Evans, Karim Fizazi, Anthony M. Joshua, Choung‐Soo Kim, Go Kimura, Paul N. Mainwaring, Harry H. Mansbach, Kurt Miller, Sarah B. Noonberg, Frank Perabo, De Phung, Fred Saad, Howard I. Scher, Mary‐Ellen Taplin, Peter Venner, Bertrand Tombal,

Cancer-related Molecular Pathways

Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.